PMX-205

Summary

PMX-205 is a cyclic hexapeptide antagonist of the C5a receptor (C5aR1/CD88), structurally related to PMX-53. It is a non-systemic, orally inactive analog designed for topical or local delivery applications. PMX-205 has been investigated in preclinical models of inflammatory and neurodegenerative diseases, including Alzheimer's disease, traumatic brain injury, and inflammatory skin conditions. It demonstrates potent C5aR1 blockade with improved selectivity and pharmacological properties compared to earlier C5a antagonists.

Mechanism of Action

Selectively antagonizes the complement component C5a receptor (CD88/C5aR1), blocking C5a-mediated pro-inflammatory signaling including neutrophil activation, chemotaxis, and cytokine release without inhibiting the complement membrane attack complex (MAC) formation.

Routes of Administration

Goals & Uses

• Traumatic brain injury inflammationNeuroprotectionLow
• Inflammatory skin diseaseDermatology / Anti InflammatoryLow
• Complement-mediated inflammatory diseaseImmunomodulationLow
• Neuroinflammation reduction in Alzheimer's diseaseNeuroprotectionLow

Contraindications

• Known hypersensitivity to cyclic peptide componentsAllergyHigh

Adverse Effects

• Local irritation (topical)DermatologicalUnknown
• ImmunosuppressionImmunologicalUnknown

Drug Interactions

• Other complement inhibitors (e.g., eculizumab)Moderate

Population Constraints

• Pediatric populationsAgeRelative
• Pregnant or lactating womenReproductiveRelative
• Immunocompromised individualsImmunologicalRelative

Regulatory Status

• European UnionUnapprovedNot approved or authorized by EMA; preclinical research stage.
• United StatesUnapprovedResearch compound only; no FDA IND or NDA on public record.
• United KingdomUnapprovedNo MHRA authorization; research use only.

PMX-205 is not approved by any regulatory authority. It remains a research-stage compound used primarily in preclinical animal models. No IND or clinical trial registration has been publicly confirmed.

Evidence & Sources

No sources recorded yet.